Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension

Emily S. Lau, Elizabeth Liu, Samantha M. Paniagua, Amy A. Sarma, Giovanna Zampierollo, Begoña López, Javier Díez, Thomas J. Wang, Jennifer E. Ho

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

We investigated the effect of galectin-3 (Gal-3) inhibition with modified citrus pectin on markers of collagen metabolism in a proof-of-concept randomized placebo-controlled trial of participants with elevated Gal-3 levels and hypertension. Although higher Gal-3 levels were associated with female sex, diabetes, and reduced glomerular filtration rate in cross-sectional analyses, treatment with modified citrus pectin did not change collagen markers. The effect of Gal-3 inhibition among individuals with heart failure warrants further investigation.

Original languageEnglish (US)
Pages (from-to)12-21
Number of pages10
JournalJACC: Basic to Translational Science
Volume6
Issue number1
DOIs
StatePublished - Jan 2021

Keywords

  • cardiac fibrosis
  • galectin-3
  • heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension'. Together they form a unique fingerprint.

Cite this